For the quarter ending 2025-09-30, FULC had $4,486K increase in cash & cash equivalents over the period. -$14,280K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -19,595 | -34,951 |
| Depreciation expense | 346 | 697 |
| Stock-based compensation expense | 3,360 | 6,042 |
| Net accretion of discounts on marketable securities | 586 | 1,984 |
| Unbilled accounts receivable | 0 | -2,096 |
| Prepaid expenses and other current assets | -44 | -1,544 |
| Operating lease assets and liabilities | 195 | 353 |
| Other assets | -3 | 2 |
| Accounts payable | 946 | 587 |
| Accrued expenses and other liabilities | 1,487 | -2,753 |
| Net cash (used in) provided by operating activities | -14,190 | -29,077 |
| Purchases of marketable securities | 17,293 | 136,790 |
| Maturities of marketable securities | 35,995 | 150,011 |
| Purchases of property and equipment | 90 | 65 |
| Net cash provided by investing activities | 18,612 | 13,156 |
| Proceeds from issuance of common stock under benefit plans, net | 64 | 301 |
| Net cash provided by financing activities | 64 | 301 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 4,486 | -15,620 |
| Cash and cash equivalents at beginning of period | 59,413 | - |
| Cash and cash equivalents at end of period | 48,279 | - |
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)